PHAT

Phathom Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth 7/10
  • Value 2/10
Phathom Pharmaceuticals sales and earnings growth
PHAT Growth
Good
  • Revenue Y/Y 121.20%
  • EPS Y/Y 59.54%
  • FCF Y/Y 65.43%
Phathom Pharmaceuticals gross and profit margin trends
PHAT Profitability
Good
  • Gross margin 84.90%
  • EPS margin -76.80%
  • ROIC 5Y -51.38%
Phathom Pharmaceuticals net debt vs free cash flow
PHAT Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 3.4
  • Interest coverage -1.4

Phathom Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks